Pfizer Inc. (PFE) vs. BioNTech SE (BNTX): Which Pharma Giant Is Better Positioned for the Post-COVID Era?

Pfizer Inc. (NYSE:PFE): Execution and Cost-Cutting Offset COVID Headwinds

Pfizer Inc. delivered a coagulated quarter, posting Q2 2026 revenues of $15.0 billion, a 1% operational summation year-over-year. Excluding Comirnaty and Paxlovid, gross grew 5% operationally, fueled by beardown show successful non-COVID products. Key drivers included Eliquis (up 19% operationally), Padcev (up 23%), Lorbrena (up 37%), and the Vyndaqel household (up 8%). Altogether, launched and acquired products surged 18% operationally. On the bottommost line, Pfizer posted a reported nonaccomplishment per stock of $(0.04) owed to a $4.3 cardinal non-cash intangible plus impairment, but delivered Adjusted Diluted EPS of $0.77.

To support fiscal momentum, Pfizer raised its full-year 2026 gross guidance by $500 cardinal to $60.5–$62.5 billion, reflecting a $1.5 cardinal outperform successful non-COVID products offsetting little COVID-19 income (revised down to $4 cardinal from $5 billion). CEO Dr. Albert Bourla highlighted momentum crossed the obesity programme and oncology portfolio. Furthermore, Pfizer announced an enlargement of its productivity enhancement initiatives expected to output $2.5 cardinal successful further savings betwixt 2027 and 2029. Pfizer reaffirmed full-year Adjusted EPS guidance of $2.80 to $2.00, which absorbs a $0.10 interaction from its Innovent Biologics transaction. Capital allocation remains disciplined, with $5.3 cardinal reinvested into interior R&D, $4.9 cardinal paid retired successful dividends, and nary stock repurchases completed year-to-date arsenic the institution focuses connected de-leveraging.

BioNTech SE (NASDAQ:BNTX): Deepening Losses Amid a Leadership Hand-Off

BioNTech SE faced a importantly tougher fiscal scenery arsenic COVID-19 vaccine request continued to fall. Q2 2026 revenues fell 59.5% year-over-year to €105.6 cardinal (down from €260.8 million), driving the company's IFRS nett nonaccomplishment to widen to €820.8 million, oregon €3.24 per diluted share. Driven by little request and timing, BioNTech chopped its full-year 2026 gross guidance to €1.6–€1.9 cardinal (down from €2.0–€2.3 billion). Despite commercialized top-line pressure, BioNTech maintains a fortress equilibrium expanse with €16.6 cardinal successful cash, currency equivalents, and information investments.